I first learned about echo at the beginning of the decade. I rode them down from around $10 and gave up but I always thought they were a good bio without a good product. Maybe they'll get their justice this year. This non-invasive monitoring is a wonderful technology IMHO.
It's a huge breakthrough. The technology will improve over time - but this is good enough to make investors very happy. The results weren't just good, they were through the roof.
But as an investor in small cap biotechs, I know that patience and timing are important. So I don't know if we'll go lower from here. We may or may not. But even if we do, I am expecting EU approval and to see the stock price as a minimum of $3 per share in 2013. Hopefully much more.